The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Toll‐like receptors: the swiss army knife of immunity and vaccine development
Open accessAbstract
Innate immune cells have a critical role in defense against infection and disease. Central to this is the broad specificity with which they can detect pathogen‐associated patterns and danger‐associated patterns via the pattern recognition receptors (PRRs) they express. Several families of PRRs have been identified including: Toll‐like receptors (TLRs), C‐type lectin‐like receptors, retinoic acid‐inducible gene‐like receptors and nucleotide‐binding oligomerization domain–like receptors. TLRs are one of the most largely studied families of PRRs. The binding of ligands to TLRs on antigen presenting cells (APCs), mainly dendritic cells, leads to APC maturation, induction of inflammatory cytokines and the priming of naive T cells to drive acquired immunity. Therefore, activation of TLRs promotes both innate inflammatory responses and the induction of adaptive immunity. Consequently, in the last two decades mounting evidence has inextricably linked TLR activation with the pathogenesis of immune diseases and cancer. It has become advantageous to harness these aspects of TLR signaling therapeutically to accelerate and enhance the induction of vaccine‐specific responses and also target TLRs with the use of biologics and small molecule inhibitors for the treatment of disease. In these respects, TLRs may be considered a ‘Swiss Army’ knife of the immune system, ready to respond in a multitude of infectious and disease states. Here we describe the latest advances in TLR‐targeted therapeutics and the use of TLR ligands as vaccine adjuvants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity
Medzhitov, R., Preston-Hurlburt, P., & Janeway, C. A. (1997) · Nature · doi:10.1038/41131 · Cited by 5,590
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Differentiation of Effector CD4 T Cell Populations
Zhu, J., Yamane, H., & Paul, W. E. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101212 · Cited by 3,452
MD-2, a Molecule that Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4
Shimazu, R., Akashi, S., Ogata, H., Nagai, Y., Fukudome, K., Miyake, K., & Kimoto, M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.11.1777 · Cited by 2,185
Crystal Structure of the TLR1-TLR2 Heterodimer Induced by Binding of a Tri-Acylated Lipopeptide
Jin, M. S., Kim, S. E., Heo, J. Y., Lee, M. E., Kim, H. M., Paik, S.-G., Lee, H., & Lee, J.-O. (2007) · Cell · doi:10.1016/j.cell.2007.09.008 · Cited by 1,344
Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction
Fitzgerald, K. A., Palsson-McDermott, E. M., Bowie, A. G., Jefferies, C. A., Mansell, A. S., Brady, G., Brint, E., Dunne, A., Gray, P., Harte, M. T., et al. (2001) · Nature · doi:10.1038/35092578 · Cited by 1,256
Self-citationCrystal Structure of the TLR4-MD-2 Complex with Bound Endotoxin Antagonist Eritoran
Kim, H. M., Park, B. S., Kim, J.-I., Kim, S. E., Lee, J., Oh, S. C., Enkhbayar, P., Matsushima, N., Lee, H., Yoo, O. J., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.002 · Cited by 1,177
Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4
Yamamoto, M., Sato, S., Hemmi, H., Sanjo, H., Uematsu, S., Kaisho, T., Hoshino, K., Takeuchi, O., Kobayashi, M., Fujita, T., et al. (2002) · Nature · doi:10.1038/nature01182 · Cited by 994
Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
Roman, M., Martin-Orozco, E., Goodman, J. S., Nguyen, M.-D., Sato, Y., Ronaghy, A., Kornbluth, R. S., Richman, D. D., Carson, D. A., & Raz, E. (1997) · Nature Medicine · doi:10.1038/nm0897-849 · Cited by 908
The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4
Mata-Haro, V., Cekic, C., Martin, M., Chilton, P. M., Casella, C. R., & Mitchell, T. C. (2007) · Science · doi:10.1126/science.1138963 · Cited by 896
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
Stanberry, L. R., Spruance, S. L., Cunningham, A. L., Bernstein, D. I., Mindel, A., Sacks, S., Tyring, S., Aoki, F. Y., Slaoui, M., Denis, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011915 · Cited by 794
Structural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA
Liu, L., Botos, I., Wang, Y., Leonard, J. N., Shiloach, J., Segal, D. M., & Davies, D. R. (2008) · Science · doi:10.1126/science.1155406 · Cited by 733
Barton, G. M., Kagan, J. C., & Medzhitov, R. (2006) · Nature Immunology · doi:10.1038/ni1280 · Cited by 670
Structure and Function of Toll Receptors and Their Ligands
Gay, N. J., & Gangloff, M. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.060305.151318 · Cited by 667
The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy
Tanga, F. Y., Nutile-McMenemy, N., & DeLeo, J. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501634102 · Cited by 634
Structural Basis of TLR5-Flagellin Recognition and Signaling
Yoon, S.-I., Kurnasov, O., Natarajan, V., Hong, M., Gudkov, A. V., Osterman, A. L., & Wilson, I. A. (2012) · Science · doi:10.1126/science.1215584 · Cited by 582
Toll‐like receptor 9 binds single‐stranded CpG‐DNA in a sequence‐ and pH‐dependent manner
Rutz, M., Metzger, J., Gellert, T., Luppa, P., Lipford, G. B., Wagner, H., & Bauer, S. (2004) · European Journal of Immunology · doi:10.1002/eji.200425218 · Cited by 503
Toll-like receptors: linking innate and adaptive immunity
Pasare, C., & Medzhitov, R. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2004.08.018 · Cited by 453
Sokal, E. M., Hoppenbrouwers, K., Vandermeulen, C., Moutschen, M., Léonard, P., Moreels, A., Haumont, M., Bollen, A., Smets, F., & Denis, M. (2007) · The Journal of Infectious Diseases · doi:10.1086/523813 · Cited by 426
TLR13 Recognizes Bacterial 23 S rRNA Devoid of Erythromycin Resistance–Forming Modification
Oldenburg, M., Krüger, A., Ferstl, R., Kaufmann, A., Nees, G., Sigmund, A., Bathke, B., Lauterbach, H., Suter, M., Dreher, S., et al. (2012) · Science · doi:10.1126/science.1220363 · Cited by 405
Fritz, J. H., Girardin, S. E., Fitting, C., Werts, C., Mengin-Lecreulx, D., Caroff, M., Cavaillon, J.-M., Philpott, D. J., & Adib-Conquy, M. (2005) · European Journal of Immunology · doi:10.1002/eji.200526286 · Cited by 358
STUDIES ON THE O ANTIGEN OF SALMONELLA TYPHOSA
Johnson, A. G., Gaines, S., & Landy, M. (1956) · The Journal of Experimental Medicine · doi:10.1084/jem.103.2.225 · Cited by 358
Structural Reorganization of the Toll-Like Receptor 8 Dimer Induced by Agonistic Ligands
Tanji, H., Ohto, U., Shibata, T., Miyake, K., & Shimizu, T. (2013) · Science · doi:10.1126/science.1229159 · Cited by 348
Wille-Reece, U., Flynn, B. J., Loré, K., Koup, R. A., Kedl, R. M., Mattapallil, J. J., Weiss, W. R., Roederer, M., & Seder, R. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507484102 · Cited by 332
Turley, C. B., Rupp, R. E., Johnson, C., Taylor, D. N., Wolfson, J., Tussey, L., Kavita, U., Stanberry, L., & Shaw, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.041 · Cited by 294
Lebwohl, M., Dinehart, S., Whiting, D., Lee, P. K., Tawfik, N., Jorizzo, J., Lee, J. H., & Fox, T. L. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.12.010 · Cited by 293
Drachenberg, K. J., Wheeler, A. W., Stuebner, P., & Horak, F. (2001) · Allergy · doi:10.1034/j.1398-9995.2001.056006498.x · Cited by 285
Shirota, Y., Shirota, H., & Klinman, D. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101304 · Cited by 257
van Dissel, J. T., Joosten, S. A., Hoff, S. T., Soonawala, D., Prins, C., Hokey, D. A., O’Dee, D. M., Graves, A., Thierry-Carstensen, B., Andreasen, L. V., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.10.036 · Cited by 243
Penny, M. A., Verity, R., Bever, C. A., Sauboin, C., Galactionova, K., Flasche, S., White, M. T., Wenger, E. A., Van de Velde, N., Pemberton-Ross, P., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00725-4 · Cited by 235
Kruit, W. H. J., Suciu, S., Dreno, B., Mortier, L., Robert, C., Chiarion-Sileni, V., Maio, M., Testori, A., Dorval, T., Grob, J.-J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7111 · Cited by 227
Bonham, K. S., Orzalli, M. H., Hayashi, K., Wolf, A. I., Glanemann, C., Weninger, W., Iwasaki, A., Knipe, D. M., & Kagan, J. C. (2014) · Cell · doi:10.1016/j.cell.2014.01.019 · Cited by 220
Gorden, K. K. B., Qiu, X. X., Binsfeld, C. C. A., Vasilakos, J. P., & Alkan, S. S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6584 · Cited by 203
The Effects of TLR Activation on T-Cell Development and Differentiation
Jin, B., Sun, T., Yu, X.-H., Yang, Y.-X., & Yeo, A. E. T. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/836485 · Cited by 201
Endotoxin can induce MyD88-deficient dendritic cells to support Th2 cell differentiation
Kaisho, T. (2002) · International Immunology · doi:10.1093/intimm/dxf039 · Cited by 197
Role of adapters in Toll-like receptor signalling
Akira, S., Yamamoto, M., & Takeda, K. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310637 · Cited by 187
Active-specific immunotherapy for melanoma.
Mitchell, M. S., Harel, W., Kempf, R. A., Hu, E., Kan-Mitchell, J., Boswell, W. D., Dean, G., & Stevenson, L. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.5.856 · Cited by 184
Taylor, D. N., Treanor, J. J., Strout, C., Johnson, C., Fitzgerald, T., Kavita, U., Ozer, K., Tussey, L., & Shaw, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.001 · Cited by 160
Signalling of Toll-Like Receptors
Brikos, C., & O'Neill, L. A. J. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-72167-3_2 · Cited by 159
Role of Toll‐like receptors in costimulating cytotoxic T cell responses
Schwarz, K., Storni, T., Manolova, V., Didierlaurent, A. M., Sirard, J., Röthlisberger, P., & Bachmann, M. F. (2003) · European Journal of Immunology · doi:10.1002/eji.200323919 · Cited by 155
Kumar, H., Koyama, S., Ishii, K. J., Kawai, T., & Akira, S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.683 · Cited by 150
Dai, J., Megjugorac, N. J., Amrute, S. B., & Fitzgerald-Bocarsly, P. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.1535 · Cited by 147
Effectiveness of Lipid and Lipidophilic Substances as Adjuvants
Dresser, D. W. (1961) · Nature · doi:10.1038/1911169a0 · Cited by 146
TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin
Vijay‐Kumar, M., Carvalho, F. A., Aitken, J. D., Fifadara, N. H., & Gewirtz, A. T. (2010) · European Journal of Immunology · doi:10.1002/eji.201040421 · Cited by 145
Hirsh, V., Paz-Ares, L. G., Boyer, M. J., Rosell, R., Middleton, G., Eberhardt, W., Szczęsna, A., Reiterer, P., Saleh, M. N., Arrieta, O. G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8971 · Cited by 141
Analysis of lipopolysaccharide binding by CD14.
Kirkland, T. N., Finley, F., Leturcq, D., Moriarty, A. M., Lee, J., Ulevitch, R. J., & Tobias, P. S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74538-4 · Cited by 137
Lysakova-Devine, T., Keogh, B., Harrington, B., Nagpal, K., Halle, A., Golenbock, D. T., Monie, T. P., & Bowie, A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002013 · Cited by 137
Manegold, C., van Zandwijk, N., Szczęsna, A., Zatloukal, P., Au, J. S. K., Błasińska-Morawiec, M., Serwatowski, P., Krzakowski, M. J., Jassem, J., Tan, E. H., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr030 · Cited by 130
Dange, R. B., Agarwal, D., Teruyama, R., & Francis, J. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0242-7 · Cited by 125
Ichinohe, T., Tamura, S., Kawaguchi, A., Ninomiya, A., Imai, M., Itamura, S., Odagiri, T., Tashiro, M., Takahashi, H., Sawa, H., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/521304 · Cited by 122
Moore, A., McCarthy, L., & Mills, K. H. G. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00062-6 · Cited by 121
Santini-Oliveira, M., Coler, R. N., Carvalho-Parra, J. F., Veloso, V. G., Jayashankar, L., Pinto, P. M., Ciol, M. A., Bergquist, R. N., Reed, S. G., & Tendler, M. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.027 · Cited by 115
Fourcade, J. J., Kudela, P., Filho, P. A. A., Janjic, B. M., Land, S. R., Sander, C., Krieg, A. Μ., Donnenberg, A. D., Shen, H., Kirkwood, J. M., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318183af0b · Cited by 109
Dimerization of Toll-like Receptor 3 (TLR3) Is Required for Ligand Binding
Wang, Y., Liu, L., Davies, D. R., & Segal, D. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.167973 · Cited by 92
Meng, W., Yamazaki, T., Nishida, Y., & Hanagata, N. (2011) · BMC Biotechnology · doi:10.1186/1472-6750-11-88 · Cited by 74
A prophylactic hepatitis B vaccine with a novel adjuvant system
Thoelen, S., Clercq, N. D., & Tornieporth, N. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00462-x · Cited by 71
Rolan, P. E., Gibbons, J. A., He, L., Chang, E., Jones, D., Gross, M. I., Davidson, J. B., Sanftner, L. M., & Johnson, K. W. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03270.x · Cited by 70
Pichyangkul, S., Gettayacamin, M., MILLER, R., Lyon, J. A., Angov, E., Tongtawe, P., RUBLE, D., HEPPNERJR, D., Kester, K. E., & Ballou, W. R. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.07.023 · Cited by 69
Morefield, G. L., Hawkins, L. D., Ishizaka, S. T., Kissner, T. L., & Ulrich, R. G. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00153-07 · Cited by 58
Bhatla, N., Suri, V., Basu, P. S., Shastri, S. S., Datta, S. K., Bi, D., Descamps, D., Bock, H. L., & the Indian HPV Vaccine Study Group (2010) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2009.01167.x · Cited by 55
Borsutzky, S., Ebensen, T., Link, C., Becker, P. D., Valeria Fiorelli, A., Cafaro, A., Ensoli, B., & Guzmán, C. A. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.11.025 · Cited by 55
Wong, Y. N., Rossignol, D. P., Rose, J., Kao, R., Carter, A. R., & Lynn, M. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003254804 · Cited by 54
Odegard, J., Flynn, P., Campbell, D. J., Robbins, S. H., Dong, L., Wang, K., ter Meulen, J., Cohen, J. I., & Koelle, D. M. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.137 · Cited by 54
Matzner, P., Sorski, L., Shaashua, L., Elbaz, E., Lavon, H., Melamed, R., Rosenne, E., Gotlieb, N., Benbenishty, A., Reed, S. G., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29885 · Cited by 51
E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes
Czeslick, E. G., Struppert, A., Simm, A., & Sablotzki, A. (2006) · Inflammation Research · doi:10.1007/s00011-006-6057-3 · Cited by 51
Baldridge, J. R., Cluff, C. W., Evans, J. T., Lacy, M. J., Stephens, J. R., Brookshire, V. G., Wang, R., Ward, J. R., Yorgensen, Y. M., Persing, D. H., et al. (2002) · Journal of Endotoxin Research · doi:10.1177/09680519020080061501 · Cited by 45
Moreno‐Eutímio, M. A., Tenorio-Calvo, A. V., Pastelin‐Palacios, R., Perez‐Shibayama, C., Gil‐Cruz, C., López‐Santiago, R., Baeza, I., Fernández‐Mora, M., Bonifaz, L. C., Isibasi, A., et al. (2013) · Immunology · doi:10.1111/imm.12093 · Cited by 44
Isambert, N., Fumoleau, P., Paul, C., Ferrand, C., Zanetta, S., Bauer, J., Ragot, K., Lizard, G., Jeannin, J., & Bardou, M. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-172 · Cited by 43
Gaddis, D. E., Michalek, S. M., & Katz, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003192 · Cited by 41
A TLR5 Agonist Inhibits Acute Renal Ischemic Failure
Fukuzawa, N., Petro, M., Baldwin, W. M., Gudkov, A. V., & Fairchild, R. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003238 · Cited by 40
Lal, H., Zahaf, T., & Heineman, T. C. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24269 · Cited by 31
Toll-Like Receptors: Ligands, Cell-Based Models, and Readouts for Receptor Action
Dowling, J. K., & Dellacasagrande, J. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3335-8_1 · Cited by 24
Self-citationBurke, J. M., Ganley-Leal, L. M., Khatri, A., & Wetzler, L. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3222 · Cited by 16
Cited by
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 804
Progress in biopharmaceutical development
Kesik‐Brodacka, M. (2018) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1617 · Cited by 353
TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
Luchner, M., Reinke, S., & Milicic, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020142 · Cited by 285
Immunotherapies targeting stimulatory pathways and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., Manochakian, R., Zhao, Y., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01085-3 · Cited by 52
Metadata
- Authors
- Dowling, J. K., & Mansell, A.
- Venue
- Clinical & Translational Immunology
- Publisher
- Wiley
- Published
- 2016-05
- Volume
- 5
- Issue
- 5
- Pages
- e85-e85
- ISSN
- 2050-0068 (ISSN-L)
- OpenAlex
- W2394725514
- Cited by
- 273
- References
- 74
- FWCI
- 21.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.